CTOs on the Move

Ideaya Biosciences

www.ideayabio.com

 
IDEAYA Biosciences is an oncology-focused biotechnology company committed to the discovery of personalized synthetic lethality medicines targeting DNA damage and repair for genetically defined patient populations and immuno-oncology therapies targeting the tumor microenvironment. Founded in 2015, IDEAYA`s investors include 5AM Ventures (5AM), Canaan Partners (Canaan), Celgene, WuXi Healthcare Ventures (WuXi), Novartis Institute of Biomedical Research, and Alexandria Real Estate. The Company has assembled a world-class drug discovery team and Scientific Advisory Board (SAB) that is represented by a Nobel Laureate and three Members of the National Academy of Sciences. IDEAYA is located in South San Francisco and La Jolla, California.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.ideayabio.com
  • 7000 Shoreline Court Suite 350
    South San Francisco, CA USA 94080
  • Phone: 650.443.6209

Executives

Name Title Contact Details
Solomon Wang
Director, IT Profile

Funding

Ideaya Biosciences raised $94M on 03/15/2018
Ideaya Biosciences raised $86.1M on 07/07/2021

Similar Companies

IRX Therapeutics

IRX Therapeutics is a Farmingdale, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ACEA Biosciences

ACEA Biosciences is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Vaxart

Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using tablets that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary tablet vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart's development programs currently include tablet vaccines designed to protect against coronavirus, norovirus, seasonal influenza, and respiratory syncytial virus (RSV), as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart's first immuno-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.

STIMIT

STIMIT`s proprietary technology enables extended local delivery of cancer immunotherapy in the context of tumor resection, the standard of care for most patients with solid tumors. Concentrating and retaining the action of potent immunomodulators locally dramatically improves the efficacy and safety of these compounds relative to administration in solution, whether via intravenous or even intratumoral injection.

Alsius Corporation

Alsius Corporation (Alsius) is a commercial-stage medical device company that develops, manufactures and sells products to precisely control patient temperature in hospital critical care settings. The Company operates through its wholly owned subsidiary,